Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Apixaban Action Pathway (new)
Homo sapiens
Drug Action Pathway
Apixaban is an oral anticoagulant drug that competitively inhibits free and bound coagulation factor X in the clotting cascade. This mechanism of action prevents the formation of a thrombus otherwise known as a blood clot. Administered orally, this drug is typically used for the prevention of strokes or systemic embolism. Used in the treatment and prevention of recurrent thromboembolic diseases, such as deep vein thrombosis and pulmonary embolisms. Apixaban is metabolized by both CYP3A4 and P-glycoprotein (P-gp) and is known to increase in the blood when these are inhibited. Apixaban enters the bloodstream through the intestine by P-gp transport.
References
Apixaban Pathway (new) References
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M: DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037.
Pubmed: 29126136
Vranckx P, Valgimigli M, Heidbuchel H: The Significance of Drug-Drug and Drug-Food Interactions of Oral Anticoagulation. Arrhythm Electrophysiol Rev. 2018 Mar;7(1):55-61. doi: 10.15420/aer.2017.50.1.
Pubmed: 29636974
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings